ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.

T. Hirose, D. Iwami, K. Hotta, H. Sasaki, H. Higuchi, N. Shinohara.

Urology, Hokkaido University, Sapporo, Japan

Meeting: 2017 American Transplant Congress

Abstract number: A49

Keywords: Antibodies, B cells

Session Information

Date: Saturday, April 29, 2017

Session Name: Poster Session A: Clinical Science: Kidney Immunosuppression: Desensitization

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Related Abstracts
  • Surviving B Cells in Different Lymphoid Organs after Rituximab Administration and Its Association with Clinical Outcomes
  • The Impact of Therapy On the Inflammatory Infiltrate in Renal Allografts With Acute and Chronic Antibody Mediated Rejection

[Introduction] Administration of rituximab to ABO-incompatible kidney transplant (ABOi-KTx) recipients is recognized as effective and safe. A single dose of 375 mg/m2 rituximab is generally sufficient for B-cell depletion. However, dosage should be adjusted according to individual response to rituximab to prevent over- and under-immunosuppression. Therefore, in this study, we aimed to determine the appropriate rituximab dosage and the target B-cell population after rituximab-based desensitization therapy .

[Materials and Methods] Forty-four consecutive ABOi-KTx recipients (28 men and 16 women) were enrolled in this retrospective study. They were administered rituximab (65–400 mg/body) 2–4 weeks before transplantation and subsequently subjected to plasmapheresis and desensitization therapy with intravenous immunoglobulin. Induction therapy with basiliximab was initiated, and the recipients were maintained on triple immunosuppressants. Their mean age at transplantation was 50.3 ± 15.4 years, and their mean pre-transplant dialysis period was 2.7 ± 3.8 years. Percentage of CD19+ B cells among the total lymphocytes (%CD19) in the peripheral blood was determined before transplantation. The recipients were divided into 2 groups according to the pre-transplant %CD19: low %CD19 group (%CD19 ≤ 1.2%; n = 35) and high %CD19 group (%CD19 > 1.2%; n = 9). The relationship between %CD19 and incidence of acute antibody-mediated rejection (AAMR) was evaluated.

[Results] AAMR was observed in 6 recipients, whose pre-transplant %CD19 was significantly higher than that of recipients who did not experience AAMR (3.1% vs. 0.6%; p = 0.004). Incidence of AAMR was significantly higher in the high %CD19 group than in the low %CD19 group (44.4% vs. 5.7%, p = 0.006). Furthermore, multivariate analysis showed that %CD19 > 1.2% was an independent factor to predict AAMR (p = 0.038).[Conclusion] High %CD19 after rituximab administration in ABOi-KTx recipients implies insufficient B-cell depletion that can lead to AAMR. Measurement of %CD19 would aid in identifying patients who need additional administration of rituximab.

CITATION INFORMATION: Hirose T, Iwami D, Hotta K, Sasaki H, Higuchi H, Shinohara N. Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hirose T, Iwami D, Hotta K, Sasaki H, Higuchi H, Shinohara N. Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/percentage-of-cd19-b-cells-as-a-predictor-of-acute-antibody-mediated-rejection-after-administration-of-rituximab-in-abo-incompatible-kidney-transplantation/. Accessed April 15, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy | Terms of Use

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.